326 related articles for article (PubMed ID: 26784543)
1. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
Doorduijn EM; Sluijter M; Querido BJ; Oliveira CC; Achour A; Ossendorp F; van der Burg SH; van Hall T
J Clin Invest; 2016 Feb; 126(2):784-94. PubMed ID: 26784543
[TBL] [Abstract][Full Text] [Related]
2. TAP-ing into TIEPPs for cancer immunotherapy.
Kiessling R
J Clin Invest; 2016 Feb; 126(2):480-2. PubMed ID: 26784539
[TBL] [Abstract][Full Text] [Related]
3. The MHC Class I Cancer-Associated Neoepitope Trh4 Linked with Impaired Peptide Processing Induces a Unique Noncanonical TCR Conformer.
Hafstrand I; Doorduijn EM; Duru AD; Buratto J; Oliveira CC; Sandalova T; van Hall T; Achour A
J Immunol; 2016 Mar; 196(5):2327-34. PubMed ID: 26800871
[TBL] [Abstract][Full Text] [Related]
4. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination.
Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJ; Offringa R; Ljunggren HG; van Hall T
Cancer Res; 2007 Sep; 67(18):8450-5. PubMed ID: 17875682
[TBL] [Abstract][Full Text] [Related]
5. The Immunogenicity of a Proline-Substituted Altered Peptide Ligand toward the Cancer-Associated TEIPP Neoepitope Trh4 Is Unrelated to Complex Stability.
Hafstrand I; Doorduijn EM; Sun R; Talyzina A; Sluijter M; Pellegrino S; Sandalova T; Duru AD; van Hall T; Achour A
J Immunol; 2018 Apr; 200(8):2860-2868. PubMed ID: 29507106
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
7. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
Marijt KA; Doorduijn EM; van Hall T
Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
[TBL] [Abstract][Full Text] [Related]
8. A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens.
Seidel UJ; Oliveira CC; Lampen MH; Hall Tv
Cancer Immunol Immunother; 2012 Jan; 61(1):119-25. PubMed ID: 22116347
[TBL] [Abstract][Full Text] [Related]
9. Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement.
Marijt KA; Griffioen L; Blijleven L; van der Burg SH; van Hall T
Cancer Immunol Immunother; 2022 Feb; 71(2):289-300. PubMed ID: 34142235
[TBL] [Abstract][Full Text] [Related]
10. Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire.
Oliveira CC; Sluijter M; Querido B; Ossendorp F; van der Burg SH; van Hall T
Mol Immunol; 2014 Nov; 62(1):129-36. PubMed ID: 24983205
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER.
Aladin F; Lautscham G; Humphries E; Coulson J; Blake N
Cancer Immunol Immunother; 2007 Aug; 56(8):1143-52. PubMed ID: 17143611
[TBL] [Abstract][Full Text] [Related]
12. Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors.
Qin Z; Harders C; Cao X; Huber C; Blankenstein T; Seliger B
Cancer Res; 2002 May; 62(10):2856-60. PubMed ID: 12019164
[TBL] [Abstract][Full Text] [Related]
13. Identification of sequences in the human peptide transporter subunit TAP1 required for transporter associated with antigen processing (TAP) function.
Ritz U; Momburg F; Pircher HP; Strand D; Huber C; Seliger B
Int Immunol; 2001 Jan; 13(1):31-41. PubMed ID: 11133832
[TBL] [Abstract][Full Text] [Related]
14. The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes by Qa-1b1.
van Hall T; Laban S; Koppers-Lalic D; Koch J; Precup C; Asmawidjaja P; Offringa R; Wiertz EJ
J Immunol; 2007 Jan; 178(2):657-62. PubMed ID: 17202325
[TBL] [Abstract][Full Text] [Related]
15. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
van Hall T; Wolpert EZ; van Veelen P; Laban S; van der Veer M; Roseboom M; Bres S; Grufman P; de Ru A; Meiring H; de Jong A; Franken K; Teixeira A; Valentijn R; Drijfhout JW; Koning F; Camps M; Ossendorp F; Kärre K; Ljunggren HG; Melief CJ; Offringa R
Nat Med; 2006 Apr; 12(4):417-24. PubMed ID: 16550190
[TBL] [Abstract][Full Text] [Related]
16. Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL.
Durgeau A; El Hage F; Vergnon I; Validire P; de Montpréville V; Besse B; Soria JC; van Hall T; Mami-Chouaib F
J Immunol; 2011 Dec; 187(11):5532-9. PubMed ID: 22025554
[TBL] [Abstract][Full Text] [Related]
17. Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival.
Lou Y; Basha G; Seipp RP; Cai B; Chen SS; Moise AR; Jeffries AP; Gopaul RS; Vitalis TZ; Jefferies WA
Clin Cancer Res; 2008 Mar; 14(5):1494-501. PubMed ID: 18316574
[TBL] [Abstract][Full Text] [Related]
18. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis.
Johnsen AK; Templeton DJ; Sy M; Harding CV
J Immunol; 1999 Oct; 163(8):4224-31. PubMed ID: 10510359
[TBL] [Abstract][Full Text] [Related]
19. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry.
Weinzierl AO; Rudolf D; Hillen N; Tenzer S; van Endert P; Schild H; Rammensee HG; Stevanović S
Eur J Immunol; 2008 Jun; 38(6):1503-10. PubMed ID: 18446792
[TBL] [Abstract][Full Text] [Related]
20. Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas.
Setiadi AF; David MD; Chen SS; Hiscott J; Jefferies WA
Cancer Res; 2005 Aug; 65(16):7485-92. PubMed ID: 16103103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
